Amylin Diabetes Drug Byetta Tops Its Rival, Januvia

September 10, 2008

Amylin Pharmaceuticals Inc. and Eli Lilly and Co. are happy with the news from a recent trial.  The trial has shown that their drug, Byetta beat out its rival fromo Merck & Co., Januvia......Washington (ChattahBox) – Amylin Pharmaceuticals Inc. and Eli Lilly and Co. are happy with the news from a recent trial.  The trial has shown that their drug, Byetta beat out its rival fromo Merck & Co., Januvia.

The results of the head-to-head trial were shown at the European Association for the Study of Diabetes in Rome.

The trial was carried out over the course of four-weeks, and focused on putting the diabetes drugs Byetta and Januvia head to head.

What they found in the four-week trial on 61 patients was that Byetta was more effective than Januvia.

The trial showcased that Byetta patients were able to better control gluclose levels compared directly to Januvia.

Byetta patients also made far better use of insulin in their body.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.